Eurofins Scientific (ERF) Q3 2024 earnings summary

Executive summary

• 9M 2024 revenues reached €5,142m, up 6.7% year-over-year, driven by strong organic growth in the Core Business, despite FX headwinds and BioPharma pipeline reset impacts.

• Profitability and cash flow objectives for 2024 are reaffirmed, with higher profit margins expected and continued confirmation of 2027 targets.

• Q3 growth was softer in North America due to BioPharma and Agroscience declines, but Food, Environment, and Consumer Testing outperformed objectives.

• Significant expansion in service offerings, including sustainability and deforestation impact assessments, and new laboratory openings.

• M&A activity included 24 acquisitions in 9M 2024, contributing €77m to revenues, with lower spend freeing capital for share buybacks.

Financial highlights

• Q3 2024 reported revenues were €1,723m, up 7.0% year-over-year, with Core Business organic growth at 4.4%.

• FX headwinds reduced revenue growth by 0.5% in 9M 2024.

• Start-ups contributed 0.9% to organic growth in 9M 2024.

• Profitability and margins remained above plan in Q3, despite revenue being slightly below expectations due to currency headwinds and softer organic growth in BioPharma.

• Cash flow objectives for the year are expected to be met, with continued confirmation of 2027 targets.

Outlook and guidance

• FY 2024 revenue expected close to €7bn, adjusted EBITDA €1.525bn–€1.575bn, and FCFF before investment in owned sites €800m–€840m.

• Mid-term (FY 2027) objectives: revenue approaching €10bn, margin 24%, adjusted EBITDA approaching €1.5bn, and financial leverage below 1.5x.

• 2025+ outlook: continued strength in Life and Consumer & Technology Products Testing, low-to-mid single digit growth in Clinical Diagnostics, strong BioPharma rebound expected in H2 2025.

• Agrosciences outlook remains uncertain due to client R&D spending reductions and regulatory factors.

• 6.5% annual average organic growth target for 2025 reaffirmed, not solely contingent on BioPharma clinical trial recovery.